Antibody therapy for histoplasmosis

Detalhes bibliográficos
Autor(a) principal: Nosanchuk, Joshua D.
Data de Publicação: 2012
Outros Autores: Zancopé-Oliveira, Rosely M., Hamilton, Andrew J., Guimarães, Allan J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/36512
Resumo: Albert Einstein College of Medicine. Department of Medicine. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA.
id CRUZ_d71e75b52b82d8d10d854cb936878628
oai_identifier_str oai:www.arca.fiocruz.br:icict/36512
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Nosanchuk, Joshua D.Zancopé-Oliveira, Rosely M.Hamilton, Andrew J.Guimarães, Allan J.2019-10-17T12:53:58Z2019-10-17T12:53:58Z2012NOSANCHUK, Joshua D. et al. Antibody therapy for histoplasmosis. Frontiers in Microbiology, v. 3, n. 21, p. 1-7, Feb. 2012.1664-302Xhttps://www.arca.fiocruz.br/handle/icict/3651210.3389/fmicb.2012.000211664-302XengFrontiers MediaAntibody therapy for histoplasmosisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleAlbert Einstein College of Medicine. Department of Medicine. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Micologia. Setor de Imunodiagnóstico. Rio de Janeiro, RJ, Brasil.Kings College. Guys Hospital. Dermatology Laboratory. London, UK.Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Professor Paulo de Góes. Departmento de Imunologia. Rio de Janeiro, RJ, Brasil.The endemic human pathogenic fungus Histoplasma capsulatum is a major fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10 years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.Histoplasma capsulatumHistoplasmosisAntibodyHistone 2BHeat shock protein 60M antigenCo-stimulationinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/36512/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALve_Nosanchuk_Joshua_etal_INI_2012.pdfve_Nosanchuk_Joshua_etal_INI_2012.pdfapplication/pdf3932936https://www.arca.fiocruz.br/bitstream/icict/36512/2/ve_Nosanchuk_Joshua_etal_INI_2012.pdf9deaf08640346610d752288faa27314fMD52TEXTve_Nosanchuk_Joshua_etal_INI_2012.pdf.txtve_Nosanchuk_Joshua_etal_INI_2012.pdf.txtExtracted texttext/plain45084https://www.arca.fiocruz.br/bitstream/icict/36512/3/ve_Nosanchuk_Joshua_etal_INI_2012.pdf.txt0fd54e7e700c6bdfc01092277bff4478MD53icict/365122019-10-18 02:01:49.198oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352019-10-18T05:01:49Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Antibody therapy for histoplasmosis
title Antibody therapy for histoplasmosis
spellingShingle Antibody therapy for histoplasmosis
Nosanchuk, Joshua D.
Histoplasma capsulatum
Histoplasmosis
Antibody
Histone 2B
Heat shock protein 60
M antigen
Co-stimulation
title_short Antibody therapy for histoplasmosis
title_full Antibody therapy for histoplasmosis
title_fullStr Antibody therapy for histoplasmosis
title_full_unstemmed Antibody therapy for histoplasmosis
title_sort Antibody therapy for histoplasmosis
author Nosanchuk, Joshua D.
author_facet Nosanchuk, Joshua D.
Zancopé-Oliveira, Rosely M.
Hamilton, Andrew J.
Guimarães, Allan J.
author_role author
author2 Zancopé-Oliveira, Rosely M.
Hamilton, Andrew J.
Guimarães, Allan J.
author2_role author
author
author
dc.contributor.author.fl_str_mv Nosanchuk, Joshua D.
Zancopé-Oliveira, Rosely M.
Hamilton, Andrew J.
Guimarães, Allan J.
dc.subject.en.pt_BR.fl_str_mv Histoplasma capsulatum
Histoplasmosis
Antibody
Histone 2B
Heat shock protein 60
M antigen
Co-stimulation
topic Histoplasma capsulatum
Histoplasmosis
Antibody
Histone 2B
Heat shock protein 60
M antigen
Co-stimulation
description Albert Einstein College of Medicine. Department of Medicine. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA.
publishDate 2012
dc.date.issued.fl_str_mv 2012
dc.date.accessioned.fl_str_mv 2019-10-17T12:53:58Z
dc.date.available.fl_str_mv 2019-10-17T12:53:58Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv NOSANCHUK, Joshua D. et al. Antibody therapy for histoplasmosis. Frontiers in Microbiology, v. 3, n. 21, p. 1-7, Feb. 2012.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/36512
dc.identifier.issn.pt_BR.fl_str_mv 1664-302X
dc.identifier.doi.none.fl_str_mv 10.3389/fmicb.2012.00021
dc.identifier.eissn.none.fl_str_mv 1664-302X
identifier_str_mv NOSANCHUK, Joshua D. et al. Antibody therapy for histoplasmosis. Frontiers in Microbiology, v. 3, n. 21, p. 1-7, Feb. 2012.
1664-302X
10.3389/fmicb.2012.00021
url https://www.arca.fiocruz.br/handle/icict/36512
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/36512/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/36512/2/ve_Nosanchuk_Joshua_etal_INI_2012.pdf
https://www.arca.fiocruz.br/bitstream/icict/36512/3/ve_Nosanchuk_Joshua_etal_INI_2012.pdf.txt
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
9deaf08640346610d752288faa27314f
0fd54e7e700c6bdfc01092277bff4478
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324751300558848

Registros relacionados